Hemogenyx Pharmaceuticals PLC (HEMO) — Cash Flow-to-Debt Ratio
Hemogenyx Pharmaceuticals PLC (HEMO) has a Cash Flow-to-Debt Ratio of -0.53x as of December 2024, meaning its operating cash flow of GBX-1.78 Million could theoretically repay -1% of its total liabilities (GBX3.36 Million) in one year. See Hemogenyx Pharmaceuticals PLC free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hemogenyx Pharmaceuticals PLC Cash Flow-to-Debt Ratio (2015–2024)
Historical debt coverage capacity for Hemogenyx Pharmaceuticals PLC across 10 annual periods. Also explore Hemogenyx Pharmaceuticals PLC net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Hemogenyx Pharmaceuticals PLC (2015–2024)
Year-by-year debt coverage analysis for Hemogenyx Pharmaceuticals PLC. For market capitalisation and broader financial context, see market value of Hemogenyx Pharmaceuticals PLC.
| Year | CF-to-Debt Ratio | Operating CF (GBX) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.23x | GBX-4.12 Million | GBX3.36 Million | ▲ +33.2% |
| 2023 | -1.84x | GBX-6.11 Million | GBX3.32 Million | ▼ -142.8% |
| 2022 | -0.76x | GBX-2.91 Million | GBX3.85 Million | ▲ +89.8% |
| 2021 | -7.45x | GBX-2.63 Million | GBX352.84K | ▼ -640.7% |
| 2020 | -1.01x | GBX-1.80 Million | GBX1.79 Million | ▼ -17.2% |
| 2019 | -0.86x | GBX-1.20 Million | GBX1.40 Million | ▲ +15.0% |
| 2018 | -1.01x | GBX-1.35 Million | GBX1.34 Million | ▲ +41.3% |
| 2017 | -1.72x | GBX-452.98K | GBX263.69K | ▲ +11.3% |
| 2016 | -1.94x | GBX-278.15K | GBX143.69K | ▼ -599506.7% |
| 2015 | 0.00x | GBX79.71 | GBX246.83K | — |